Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tysabri

- PMLiVE

Merck KGaA and Opexa enter MS deal

Will develop personalised T-cell based medicine Tcelna

- PMLiVE

Biogen Idec posts solid Q4 results and says more to come

MS drugs Tysabri and Avonex lift sales

- PMLiVE

Biogen Idec, Elan file Tysabri for first-line use

US and EU multiple sclerosis drug submissions follow companion diagnostic approval

- PMLiVE

Biogen submits haemophilia drug for US approval

Step forward for its partnership with Swedish Orphan Biovitrum

- PMLiVE

Biogen Idec drops ALS drug dexpramipexole

Fails to achieve efficacy in phase III trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links